This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vrionis, F. D. Articles by Bigner, D. D. Search for Related Content PubMed PubMed Citation Articles by Vrionis, F. D. Articles by Bigner, D. D.

Five New Epitope-defined Monoclonal Antibodies Reactive with G_M2 and Human Glioma and Medulloblastoma Cell Lines¹

Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710 [F. D. V., C. J. W., D. D. B.], and Department of Psychiatry and Neurochemistry, Gothenburg University, St. Jorgen Hospital, 422 03 Hisings Backa, Sweden [P. F., J-E. M., L. S.]

In order to investigate G_M2 expression in gliomas, the G_M2-positive human glioma cell line (HGL) D-54 MG, which contains 0.6 nmol G_M2/mg protein, representing 77% of the total monosialoganglioside fraction, was used as an immunogen for the production of anti-G_M2 monoclonal antibodies. For ganglioside designations, see IUPAC-IUB (Eur. J. Biochem., 79: 11–21, 1977) and Svennerholm (J. Neurochem., 10: 613–623, 1963). Five IgM monoclonal antibodies (DMAb-1 through DMAb-5) specifically recognizing the GalNAcß1-4(NeuAc2-3)Gal-terminal epitope common to G_M2 and GalNAc-G_D1a are reported. The antibodies did not react with G_M1, G_M3, G_D2, G_D3, G_D1a, G_D1b, G_T1b, and G_Q1b. Purified anti-G_M2 MAbs were used to define the expression of the "G_M2" terminal epitope by cultured human malignant and normal cells by radioimmunoassay and membrane immunofluorescence. Among neuroectodermal tissue-derived cell lines, DMAb-3, at an optimal concentration of 5 µg/ml, showed high reactivity (radioimmunoassay binding ratios > 20) with 9 of 19 HGLs, 3 of 5 medulloblastoma, 4 of 5 neuroblastoma, and 1 of 3 melanoma lines. Moderate reactivity (binding ratio, 10–20) was exhibited by 3 HGL, 2 medulloblastoma, and 1 neuroblastoma lines and low reactivity (binding ratio, 3–10) by 5 HGL lines; no reactivity was detected with 2 HGL and 2 melanoma lines. Densitometric evaluation of monosi-aloganglioside extracts from human glioma and medulloblastoma cell lines in conjunction with immunostaining on thin-layer chromatograms showed that G_M2 represents the major monosialoganglioside in 8 of 10 HGL and in 3 of 4 Med lines. In these lines the amount of G_M2 ranged from <0.1 to 0.6 nmol/mg protein. These results indicate that G_M2 represents a proportionally increased ganglioside of most glioma, medulloblastoma, and neuroblastoma cells in vitro.

¹ This work was supported by NIH Grants R37 CA11898, NS 20023, and CA32672 and by grants from the Swedish Medical Research Council (Project 03X-627), Swedish Cancer Society (Project 2260-B88-01X), and the National Swedish Board for Technical Development (Project 84-4667).

² To whom requests for reprints should be addressed, at P. O. Box 3156, 207 Jones Bldg., Duke University Medical Center, Durham, NC 27710.

Received 4/12/89. Accepted 9/ 6/89.

This article has been cited by other articles:

				M. W. Retter, J. C. Johnson, D. W. Peckham, J. E. Bannink, C. S. Bangur, K. Dresser, F. Cai, T. M. Foy, N. A. Fanger, G. R. Fanger, et al. Characterization of a Proapoptotic Antiganglioside GM2 Monoclonal Antibody and Evaluation of Its Therapeutic Effect on Melanoma and Small Cell Lung Carcinoma Xenografts Cancer Res., July 15, 2005; 65(14): 6425 - 6434. [Abstract] [Full Text] [PDF]

				K. Nakamura, M. Hanibuchi, S. Yano, Y. Tanaka, I. Fujino, M. Inoue, T. Takezawa, K. Shitara, S. Sone, and N. Hanai Apoptosis Induction of Human Lung Cancer Cell Line in Multicellular Heterospheroids with Humanized Antiganglioside GM2 Monoclonal Antibody Cancer Res., October 1, 1999; 59(20): 5323 - 5330. [Abstract] [Full Text] [PDF]